Disclosure Of First-Time Adoption [Text Block]

Xspray Pharma - Filing #679276

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	Koncernens finansiella rapporter har upprättats*<	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	693 413 SEK	—	554 724 SEK	976,000 SEK	—	—	—	31 253 SEK	184,000 SEK	—	1 216 093 SEK	556 019 SEK	—	—	—	—	976,000 SEK	375 057 SEK	22 680 SEK	- SEK	907 420 SEK	—	—	243 387 SEK	976,000 SEK	813 483 SEK	591 752 SEK	- SEK	20 680 SEK
Comprehensive income	179 851 SEK	—	- SEK	—	—	179 667 SEK	184,000 SEK	- SEK	—	—	- SEK	—	—	– SEK	– SEK	131 670 SEK	131 670 SEK	—	—	—	—	—	- SEK	– SEK	—	—	—	—	—	—
Profit (loss)	179 667 SEK	—	- SEK	—	—	179 667 SEK	—	- SEK	—	—	- SEK	—	—	– SEK	– SEK	131 670 SEK	131 670 SEK	—	—	—	—	—	- SEK	– SEK	—	—	—	—	—	—